{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:21:32Z","timestamp":1792030892140,"version":"4.4.0"},"publisher-location":"Chichester, UK","reference-count":29,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd007791.pub2","type":"reference-entry","created":{"date-parts":[[2009,10,21]],"date-time":"2009-10-21T14:57:29Z","timestamp":1256137049000},"source":"Crossref","is-referenced-by-count":16,"title":["Antioxidants and other pharmacological treatments for Friedreich ataxia"],"prefix":"10.1002","author":[{"given":"Mary","family":"Kearney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W","family":"Orrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Pandolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,10,7]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD007791.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1212\/01.WNL.0000055872.50364.FC","article-title":"Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial","volume":"60","author":"Mariotti","year":"2003","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD007791.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S1474-4422(07)70220-X","article-title":"Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial","volume":"6","author":"Prospero","journal-title":"The Lancet Neurology"},{"issue":"12","key":"10.1002\/14651858.CD007791.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1468-1331.2008.02318.x","article-title":"Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy","volume":"15","author":"Cooper","year":"2008","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD007791.pub2-BIB4|cit4","unstructured":"ApoPharma A study investigating the safety and tolerability of deferiprone in patients with Friedreich's ataxia http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00530127"},{"key":"10.1002\/14651858.CD007791.pub2-BIB5|cit5","unstructured":"Ipsen Efficacy of EGb761 in patients suffering from Friedreich ataxia http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00824512 Accessed February 2009"},{"key":"10.1002\/14651858.CD007791.pub2-BIB6|cit6","unstructured":"Efficacy of Epoetin Alfa in patients with Friedreich's ataxia www.clinicaltrials.gov"},{"key":"10.1002\/14651858.CD007791.pub2-BIB7|cit7","unstructured":"Santhera Pharmaceuticals IONIA (Idebenone effects On Neurological ICARS Assessments) http:\/\/hugin.info\/137261\/R\/1276710\/284373.pdf"},{"key":"10.1002\/14651858.CD007791.pub2-BIB8|cit8","unstructured":"Santhera Pharmaceuticals MICONOS (Mitochondrial protection with Idebenone in Cardiac Or Neurological Outcome Study) http:\/\/hugin.info\/137261\/R\/1276710\/284373.pdf"},{"key":"10.1002\/14651858.CD007791.pub2-BIB9|cit9","unstructured":"Effect of pioglitazone administered to patients with Friedreich's ataxia: proof of concept www.orpha.net\/data\/eth\/GB\/ID50165GB.pdf"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1055\/s-2002-34494","article-title":"Friedreich's ataxia: idebenone treatment in early stage patients","volume":"33","author":"Artuch","year":"2002","journal-title":"Neuropediatrics"},{"issue":"1","key":"10.1002\/14651858.CD007791.pub2-BIB11|cit11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2006-12-065433","article-title":"Selective iron chelation in Friedreich ataxia: biological and clinical implications","volume":"110","author":"Boddaert","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD007791.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ana.21177","article-title":"Friedreich's ataxia; clinical pilot trial with recombinant human erythropoietin","volume":"62","author":"Boesch","year":"2007","journal-title":"Annals of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD007791.pub2-BIB13|cit13","first-page":"1569","article-title":"Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring","volume":"60","author":"Buyse","journal-title":"Neurology"},{"issue":"5254","key":"10.1002\/14651858.CD007791.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich's Ataxia: Autosomal Recessive Disease caused by an Intronic GAA Triplet Repeat Expansion","volume":"271","author":"Campuzano","year":"1996","journal-title":"Science"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/jnnp.2006.096008","article-title":"How is disease progress in Friedreich ataxia best measured? A study of four rating scales","volume":"78","author":"Fahey","year":"2006","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD007791.pub2-BIB16|cit16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9149(02)02381-0","article-title":"Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy","volume":"90","author":"Grothues","year":"2002","journal-title":"American Journal Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/archneur.62.4.621","article-title":"Antioxidant treatment of patients with Friedreich ataxia: Four-year follow-up","volume":"62","author":"Hart","year":"2005","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/heart.87.4.346","article-title":"Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia","volume":"87","author":"Hausse","year":"2002","journal-title":"Heart"},{"key":"10.1002\/14651858.CD007791.pub2-BIB19|cit19","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008] The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"issue":"1","key":"10.1002\/14651858.CD007791.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0008-6363(01)00357-1","article-title":"Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study","volume":"52","author":"Lodi","year":"2001","journal-title":"Cardiovascular Research"},{"issue":"11","key":"10.1002\/14651858.CD007791.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1212\/01.wnl.0000218155.46739.90","article-title":"Measuring Friedreich ataxia. Complementary features of examination and performance measures","volume":"66","author":"Lynch","year":"2006","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD007791.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1742-2094-1-3","article-title":"Effect of pioglitazone treatment in a patient with secondary multiple sclerosis","volume":"1","author":"Pershadsingh","year":"2004","journal-title":"Journal of Neuroinflammation"},{"key":"10.1002\/14651858.CD007791.pub2-BIB23|cit23","first-page":"000","article-title":"Idebenone treatment in paediatric and adult patients with Friedreich ataxia: Long-term follow-up","volume":"000","author":"Pineda","year":"2008","journal-title":"European Journal of Paediatrics"},{"issue":"4","key":"10.1002\/14651858.CD007791.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/archneur.64.4.558","article-title":"Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up.","volume":"64","author":"Ribai","year":"2007","journal-title":"Archives of Neurology"},{"issue":"9177","key":"10.1002\/14651858.CD007791.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(99)01341-0","article-title":"Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study","volume":"354","author":"Rustin","year":"1999","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD007791.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1212\/WNL.55.11.1719","article-title":"Oxidative stress in patients with Friedreich ataxia","volume":"55","author":"Schulz","year":"2000","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD007791.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0304-3940(01)01892-4","article-title":"Idebenone in patients with Friedreich ataxia.","volume":"306","author":"Sch\u00f6ls L. Vorgerd M. Schillings M. Skipka G. Zange","year":"2001","journal-title":"Neuroscience Letters"},{"issue":"6","key":"10.1002\/14651858.CD007791.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00702-004-0216-x","article-title":"L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial","volume":"112","author":"Sch\u00f6ls","journal-title":"Journal Neural Transmission"},{"issue":"2","key":"10.1002\/14651858.CD007791.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0022-510X(96)00231-6","article-title":"International Cooperative Ataxia Rating Scale for pharmacological assessment of cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology","volume":"145","author":"Trouillas","year":"1997","journal-title":"Journal of Neurological Sciences"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD007791.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T18:13:50Z","timestamp":1628532830000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD007791.pub2"}},"subtitle":[],"editor":[{"given":"Mary","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2009,10,7]]},"references-count":29,"aliases":["10.1002\/14651858.cd007791"],"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007791.pub2","relation":{},"subject":[],"published":{"date-parts":[[2009,10,7]]}}}